HIGHLIGHTS
- who: Shuo Zhang from the Anhui Medical University, China have published the Article: Treatment of refractory lupus nephritis using leflunomide: A prospective study, in the Journal: (JOURNAL) of 28/Dec/2022
- what: In patients diagnosed with refractory LN, the study shows that leflunomide could be a promising treatment option owing to its response rate and safety profile. The aim of this study was to determine whether LEF could be effective and safe in the management of refractory LN.
- how: The authors calculated the response rate using intention-to-treat analysis. The results indicated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.